Bivalirudin in percutaneous coronary intervention for chronic total occlusion: A single‐center pilot study

Bivalirudin in percutaneous coronary intervention for chronic total occlusion: A single‐center... INTRODUCTIONAntithrombotic therapy plays an essential role in the prevention of thrombotic complications during percutaneous coronary intervention (PCI) . The benefits of antithrombotic agents must be weighed against their potential risk of hemorrhagic complications, especially in complex PCI and patients with high risk of bleeding . Unfractionated heparin (UFH) and bivalirudin have been used most commonly for anticoagulation in PCI [1]. Bivalirudin, a synthetic reversible direct thrombin inhibitor, can selectively block clot‐bound thrombin, potentially achieving a more potent and more predictable anticoagulant response than UFH . Numerous trials have consistently shown that bivalirudin could reduce bleeding complications compared with UFH . Therefore, bivalirudin appears to be a suitable alternative for anticoagulation in PCI. However, the safety and efficacy of bivalirudin in complex PCI procedure like chronic total occlusion (CTO) lesions are still uncertain.CTO is encountered in 15–30% of patients undergoing diagnostic coronary angiography . Compared to patients without CTO, CTO patients have more comorbidities, more extensive CAD and are more frequently referred for bypass surgery . Successful CTO PCI has been demonstrated to improve quality of life and left ventricular function, and reduce ischemia or the need for subsequent bypass surgery . However, CTO recanalization remains one of the most http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Catheterization and Cardiovascular Interventions Wiley

Bivalirudin in percutaneous coronary intervention for chronic total occlusion: A single‐center pilot study

Loading next page...
 
/lp/wiley/bivalirudin-in-percutaneous-coronary-intervention-for-chronic-total-wOANhAdYYM
Publisher
Wiley Subscription Services, Inc., A Wiley Company
Copyright
© 2018 Wiley Periodicals, Inc.
ISSN
1522-1946
eISSN
1522-726X
D.O.I.
10.1002/ccd.27181
Publisher site
See Article on Publisher Site

Abstract

INTRODUCTIONAntithrombotic therapy plays an essential role in the prevention of thrombotic complications during percutaneous coronary intervention (PCI) . The benefits of antithrombotic agents must be weighed against their potential risk of hemorrhagic complications, especially in complex PCI and patients with high risk of bleeding . Unfractionated heparin (UFH) and bivalirudin have been used most commonly for anticoagulation in PCI [1]. Bivalirudin, a synthetic reversible direct thrombin inhibitor, can selectively block clot‐bound thrombin, potentially achieving a more potent and more predictable anticoagulant response than UFH . Numerous trials have consistently shown that bivalirudin could reduce bleeding complications compared with UFH . Therefore, bivalirudin appears to be a suitable alternative for anticoagulation in PCI. However, the safety and efficacy of bivalirudin in complex PCI procedure like chronic total occlusion (CTO) lesions are still uncertain.CTO is encountered in 15–30% of patients undergoing diagnostic coronary angiography . Compared to patients without CTO, CTO patients have more comorbidities, more extensive CAD and are more frequently referred for bypass surgery . Successful CTO PCI has been demonstrated to improve quality of life and left ventricular function, and reduce ischemia or the need for subsequent bypass surgery . However, CTO recanalization remains one of the most

Journal

Catheterization and Cardiovascular InterventionsWiley

Published: Jan 1, 2018

Keywords: ; ; ;

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Unlimited reading

Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.

Stay up to date

Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.

Organize your research

It’s easy to organize your research with our built-in tools.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

Monthly Plan

  • Read unlimited articles
  • Personalized recommendations
  • No expiration
  • Print 20 pages per month
  • 20% off on PDF purchases
  • Organize your research
  • Get updates on your journals and topic searches

$49/month

Start Free Trial

14-day Free Trial

Best Deal — 39% off

Annual Plan

  • All the features of the Professional Plan, but for 39% off!
  • Billed annually
  • No expiration
  • For the normal price of 10 articles elsewhere, you get one full year of unlimited access to articles.

$588

$360/year

billed annually
Start Free Trial

14-day Free Trial